GlassScriptPhysician profile
Mark H Messenger
NPI 1568455517
$1,317.83
in general payments reported to CMS, 2019-2025
19 companies · $574 in 2025
The $574 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.17 · 2022: $104 · 2023: $38.39 · 2024: $579 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,171.76 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $493.15 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $201.18 | 2022-2025 | Lynparza |
| Celgene Corporation | $174.89 | 2024-2025 | Reblozyl, Pomalyst |
| Abbvie INC. | $137.20 | 2024-2025 | |
| Springworks Therapeutics, INC. | $27.44 | 2024 | Ogsiveo |
| Merck Sharp & Dohme LLC | $26.86 | 2024 | Keytruda |
| Gilead Sciences, INC. | $26.67 | 2024 | |
| Alexion Pharmaceuticals, INC. | $24.24 | 2024 | Ultomiris |
| Iovance Biotherapeutics, INC. | $23.26 | 2025 | Amtagvi |
| E.R. Squibb & Sons, L.L.C. | $22.17 | 2021 | |
| Astellas Pharma US INC | $20.84 | 2025 | Xtandi |
| Adc Therapeutics America, INC. | $20.54 | 2024 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2024 | |
| Genentech USA, INC. | $19.58 | 2024 | Polivy |
| Daiichi Sankyo INC. | $19.13 | 2024 | Injectafer |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.81 | 2025 | |
| Cti Biopharma Corp. | $15.01 | 2023 | Vonjo |
| Medtronic, INC. | $14.98 | 2024 | Arcpoint |
| Janssen Biotech, INC. | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Messenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.